563 related articles for article (PubMed ID: 24217332)
21. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
Oh WK; Miao R; Vekeman F; Sung J; Cheng WY; Gauthier-Loiselle M; Dhawan R; Duh MS
Med Oncol; 2017 Aug; 34(9):160. PubMed ID: 28795333
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
Clément-Zhao A; Auvray M; Aboudagga H; Blanc-Durand F; Angelergues A; Vano YA; Mercier F; El Awadly N; Verret B; Thibault C; Oudard S
BJU Int; 2018 Feb; 121(2):203-208. PubMed ID: 28370882
[TBL] [Abstract][Full Text] [Related]
23. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
Oudard S; Fizazi K; Sengeløv L; Daugaard G; Saad F; Hansen S; Hjälm-Eriksson M; Jassem J; Thiery-Vuillemin A; Caffo O; Castellano D; Mainwaring PN; Bernard J; Shen L; Chadjaa M; Sartor O
J Clin Oncol; 2017 Oct; 35(28):3189-3197. PubMed ID: 28753384
[TBL] [Abstract][Full Text] [Related]
24. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
25. Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.
Pobel C; Auclin E; Teyssonneau D; Laguerre B; Cancel M; Boughalem E; Noel J; Brachet PE; Maillet D; Barthelemy P; Helissey C; Thibault C; Oudard S
Cancer Med; 2021 Sep; 10(18):6304-6309. PubMed ID: 34382352
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).
Sonpavde G; Wang CG; Galsky MD; Oh WK; Armstrong AJ
BJU Int; 2015 Jul; 116(1):17-29. PubMed ID: 25046451
[TBL] [Abstract][Full Text] [Related]
27. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
Carles J; Pichler A; Korunkova H; Tomova A; Ghosn M; El Karak F; Makdessi J; Koroleva I; Barnes G; Bury D; Özatilgan A; Hitier S; Katolicka J
BJU Int; 2019 Mar; 123(3):456-464. PubMed ID: 30098093
[TBL] [Abstract][Full Text] [Related]
28. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
Oudard S
Future Oncol; 2011 Apr; 7(4):497-506. PubMed ID: 21463139
[TBL] [Abstract][Full Text] [Related]
29. [Metastatic prostate cancer : Update: position paper for the use of chemotherapy].
Ohlmann CH; Goebell PJ; Grimm MO; Klier J; König F; Machtens S; Schostak M; Schrader AJ; Albers P
Urologe A; 2017 Dec; 56(12):1597-1602. PubMed ID: 28695241
[TBL] [Abstract][Full Text] [Related]
30. Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study.
Cicero G; De Luca R; Dorangricchia P; Galvano A; Lo Re G; Serretta V; Dispensa N; Dieli F
Oncology; 2017; 92(2):94-100. PubMed ID: 27960186
[TBL] [Abstract][Full Text] [Related]
31. Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
Francini E; Fiaschi AI; Petrioli R; Laera L; Bianco V; Ponchietti R; Roviello G
Anticancer Drugs; 2015 Sep; 26(8):884-7. PubMed ID: 26053281
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
33. Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature.
Di Lorenzo G; Pagliuca M; Perillo T; Benincasa A; Bosso D; De Placido S; Buonerba C
Medicine (Baltimore); 2016 Apr; 95(14):e2754. PubMed ID: 27057826
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.
Caffo O; Ortega C; Di Lorenzo G; Sava T; De Giorgi U; Cavaliere C; Macrini S; Spizzo G; Aieta M; Messina C; Tucci M; Lodde M; Mansueto G; Zucali PA; Alesini D; D'Angelo A; Massari F; Morelli F; Procopio G; Ratta R; Fratino L; Lo Re G; Pegoraro MC; Zustovich F; Vicario G; Ruatta F; Federico P; La Russa F; Burgio SL; Maines F; Veccia A; Galligioni E
Urol Oncol; 2015 Jun; 33(6):265.e15-21. PubMed ID: 25907622
[TBL] [Abstract][Full Text] [Related]
35. Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer.
Sella A; Sella T; Peer A; Berger R; Frank SJ; Gez E; Sharide D; Hayat H; Hanovich E; Kovel S; Rosenbaum E; Neiman V; Keizman D
Clin Genitourin Cancer; 2014 Dec; 12(6):428-32. PubMed ID: 25066221
[TBL] [Abstract][Full Text] [Related]
36. Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial.
Kellokumpu-Lehtinen PL; Marttila T; Jekunen A; Hervonen P; Klintrup K; Kataja V; Utriainen T; Luukkaa M; Leskinen M; Pulkkanen K; Kautio AL; Huttunen T
Anticancer Res; 2020 Dec; 40(12):6915-6921. PubMed ID: 33288585
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.
Bracarda S; Caserta C; Galli L; Carlini P; Pastina I; Sisani M; Scali S; Hamzaj A; Derosa L; Felici A; Rossi M; Altavilla A; Chioni A; De Angelis V
Future Oncol; 2015 Nov; 11(22):3083-90. PubMed ID: 26437324
[TBL] [Abstract][Full Text] [Related]
38. [Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data].
Gschwend JE; Albers P; Bögemann M; Goebell P; Heidenreich A; Klier J; König F; Machtens S; Pantel K; Thomas C
Urologe A; 2018 Jan; 57(1):34-39. PubMed ID: 29071398
[TBL] [Abstract][Full Text] [Related]
39. Cabazitaxel for the treatment of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sartor O
Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
[TBL] [Abstract][Full Text] [Related]
40. Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer.
Al-Mansouri L; Gurney H
Asia Pac J Clin Oncol; 2019 Dec; 15(6):288-295. PubMed ID: 31313526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
